Key takeaways:
- The U.S. Court of Appeals for the Federal Circuit granted Apple’s request for a stay of the ban, which was enacted after the U.S. International Trade Commission (ITC) ruled that some Apple Watch models created since 2020 infringed on pulse-reader patents owned by the California-based biotech firm Masimo.
- The ITC had banned the import of the watches because it ruled that the tech giant had illegally used blood oxygen technology from Masimo, a medical tech company.
- The appeals court’s decision to pause the ban is a victory for Apple, which has argued that the ban would cause irreparable harm to its business.
Apple Inc. has won a temporary reprieve in its legal battle over the Apple Watch product, with an appeals court ordering a pause on a ban of the product that went into effect on Tuesday.
The U.S. Court of Appeals for the Federal Circuit granted Apple’s request for a stay of the ban, which was enacted after the U.S. International Trade Commission (ITC) ruled that some Apple Watch models created since 2020 infringed on pulse-reader patents owned by the California-based biotech firm Masimo.
The ITC had banned the import of the watches because it ruled that the tech giant had illegally used blood oxygen technology from Masimo, a medical tech company. The ban would have paused sales on the Apple Watch Series 9 and Apple Watch Ultra 2, which include a blood oxygen monitor that is at the center of a patent dispute.
Apple is appealing the ITC’s ruling, but a lower court previously decided the ban could take effect while Apple fought to reverse it. The court gave the ITC until January 10 to respond to Apple’s request for a longer stay while the issue moves through the courts, according to the ruling.
The appeals court’s decision to pause the ban is a victory for Apple, which has argued that the ban would cause irreparable harm to its business. It is unclear when the appeals court will make a final ruling on the case.
Be First to Comment